Download presentation
Presentation is loading. Please wait.
Published byΝίκανδρος Καλλιγάς Modified over 6 years ago
1
Reasons patients were excluded from the switch from atorvastatin to simvastatin
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
2
Outcome of patients originally being prescribed 10 or 20 mg atorvastatin
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
3
Total serum cholesterol before and after switching from atorvastatin to simvastatin
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
4
Total cholesterol before (closed diamonds) and after (open squares) switching from atorvastatin to simvastatin - Dotted line marks audit standard J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
5
Reasons patients were excluded from the switch from losartan to candesartan
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
6
Reasons patients were switched back to losartan
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
7
Outcome of patients originally being prescribed losartan
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
8
Blood pressure before and after switching from losartan to candesartan
J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
9
Systolic and diastolic blood pressure recordings before (closed diamonds) and after (open squares) switching from losartan to candesartan for patients without diabetes or cardiovascular disease (CVD; A), with diabetes (B) and with CVD (C). Dotted lines indicated audit standard J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
10
Outcome Representative sample of respondents’ comments on how they felt when they were asked to change their medication J. A. Usher-Smith, et al. Int J Clin Pract 2007; 61:15–23
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.